{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:02:14Z","timestamp":1771592534693,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:59:15Z","timestamp":1682009955000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-9692","authenticated-orcid":false,"given":"Yiquan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3581-7665","authenticated-orcid":false,"given":"Jingjing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-6879","authenticated-orcid":false,"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4945-544X","authenticated-orcid":false,"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-2365","authenticated-orcid":false,"given":"Xinlong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8081-0091","authenticated-orcid":false,"given":"Kan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-1475","authenticated-orcid":false,"given":"Xiaobin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-5317","authenticated-orcid":false,"given":"Qian","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-6977","authenticated-orcid":false,"given":"Shiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuange","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-5519","authenticated-orcid":false,"given":"Gen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.009_bib1","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.009_bib2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ejca.2023.04.009_bib3","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2010.33.3757","article-title":"Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer","volume":"29","author":"Zhou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2018.07.003","article-title":"The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base","volume":"123","author":"Jiao","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.04.009_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/JTO.0b013e3182641d4f","article-title":"Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma","volume":"7","author":"Yanagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40880-019-0354-z","article-title":"Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun"},{"key":"10.1016\/j.ejca.2023.04.009_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12885-015-1019-1","article-title":"MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation","volume":"15","author":"Noro","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.04.009_bib9","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.04.009_bib10","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","article-title":"Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer","volume":"23","author":"Takano","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.04.009_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1349-7006.2006.00233.x","article-title":"EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification","volume":"97","author":"Yokoyama","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2023.04.009_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer - molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.04.009_bib14","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/neuonc\/noz096","article-title":"Defining EGFR amplification status for clinical trial inclusion","volume":"21","author":"French","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11523-021-00798-2","article-title":"Clinical value of EGFR copy number gain determined by amplicon-based targeted next generation sequencing in patients with EGFR-mutated NSCLC","volume":"16","author":"Wei","year":"2021","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/cas.15655","article-title":"Absence of copy number gain of EGFR: a possible predictive marker of long-term response to afatinib","volume":"114","author":"Nakamura","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2023.04.009_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105369","article-title":"Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer","volume":"119","author":"Xu","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ejca.2023.04.009_bib20","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2023.04.009_bib21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.20892\/j.issn.2095-3941.2018.0142","article-title":"Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology","volume":"16","author":"Zhang","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ejca.2023.04.009_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.009_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-09-1660","article-title":"Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"16","author":"Dahabreh","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.04.009_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lungcan.2015.06.008","article-title":"Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients","volume":"89","author":"Shan","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.04.009_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11523-018-0594-x","article-title":"EGFR amplification and sensitizing mutations correlate with survival in lung adenocarcinoma patients treated with erlotinib (MutP-CLICaP)","volume":"13","author":"Ruiz-Patino","year":"2018","journal-title":"Target Oncol"},{"issue":"Suppl 8","key":"10.1016\/j.ejca.2023.04.009_bib27","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/neuonc\/nou294","article-title":"Molecular pathologic diagnosis of epidermal growth factor receptor","volume":"16","author":"Maire","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/neuonc\/noz146","article-title":"EGFR amplification status for clinical trial inclusion: where do we draw the line?","volume":"21","author":"Molinaro","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib29","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.21037\/jtd-20-1630","article-title":"Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer","volume":"12","author":"Gao","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2023.04.009_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2012.11.009","article-title":"Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer","volume":"79","author":"Grob","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2023.04.009_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.04.009_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007464","article-title":"Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells","volume":"4","author":"Soh","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2023.04.009_bib33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1158\/1541-7786.MCR-08-0532","article-title":"Oncogenic activating mutations are associated with local copy gain","volume":"7","author":"Modrek","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2023.04.009_bib34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/1940-6207.CAPR-08-0080","article-title":"Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops","volume":"1","author":"Gazdar","year":"2008","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ejca.2023.04.009_bib35","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12032-013-0810-6","article-title":"Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance","volume":"31","author":"Zhao","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2023.04.009_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2023.04.009_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111554","article-title":"RAC1 activation as a potential therapeutic option in metastatic cutaneous melanoma","volume":"11","author":"Colon-Bolea","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejca.2023.04.009_bib39","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","article-title":"Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third-generation EGFR tyrosine kinase inhibitor, osimertinib","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2023.04.009_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","article-title":"Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC","volume":"16","author":"Zheng","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/JTO.0000000000000034","article-title":"Erk\/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer","volume":"9","author":"Chen","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2023.04.009_bib42","first-page":"3760","article-title":"Moonlighting functions of metabolic enzymes and metabolites in cancer","volume":"81","author":"Pan","year":"2021","journal-title":"Mol\u00a0Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:15Z","timestamp":1760733615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":42,"alternative-id":["S095980492300196X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}